Last updated on September 2018

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.

Detailed Study Description

The purpose of this study is to assess whether eflornithine 500 mg or sulindac 150 mg are effective in reducing the 3-year event rate of high risk adenoma or second primary colorectal cancer in Stage 0, I II and III colon cancer patients. The primary hypothesis will test the main effect of each agent, as well as the comparison of placebo alone to the combination of sulindac and eflornithine.

Clinical Study Identifier: NCT01349881

Contact Investigators or Research Sites near you

Start Over

David M. King

Regions Hospital
Saint Paul, MN United States
0.17miles
  Connect »

David M. King

United Hospital
Saint Paul, MN United States
1.89miles
  Connect »

David M. King

Minnesota Oncology Hematology PA-Maplewood
Maplewood, MN United States
5.06miles
  Connect »

David M. King

Saint John's Hospital - Healtheast
Maplewood, MN United States
5.06miles
  Connect »

Patricia N. O'Kane, B.S.

University of Minnesota/Masonic Cancer Center
Minneapolis, MN United States
7.13miles
  Connect »

David M. King

Minnesota Oncology Hematology PA-Woodbury
Woodbury, MN United States
7.52miles
  Connect »

David M. King

Health Partners Inc
Minneapolis, MN United States
7.54miles
  Connect »

David M. King

Abbott-Northwestern Hospital
Minneapolis, MN United States
8.12miles
  Connect »

David M. King

Hennepin County Medical Center
Minneapolis, MN United States
8.36miles
  Connect »